Overview of recent advances in metastatic triple negative breast cancer

Table 6 Key phase I/II/III involving antibody drug conjugates and targeted therapies

Trial	n	Drug	ORR 1st line	ORR ≥ 2 line	mPFS ≥ 2 line	mOS 1st line	mOS ≥ 2 line	Ref.
NCT01631552 phase II	108	Sacituzumab govitecan		33%	5.5		12.4	Schmid et al[61], 2020
NCT03310957 phase I/II	51	Pembrolizumab + ladiratuzumab vedoitin	54%		-			Han et al[78], 2020
NCT029380341 phase Ib/II	21	US-1402		33%	-			Kim et al[82], 2019
NCT03279257 phase 1b/II	40	Alpelisib		57%	7			Sharma et al[84], 2018
LOTUS phase II	124	Ipatasertib		40%	6.2			Kim et al[86], 2017
NCT02978716 phase II	102	Trilaciclib	43%			20.6/17.6		Tan et al[88], 2019
ASCENT phase III	529	Sacituzumab Govitecan		35%	5.6		12.1	Bardia et al[77], 2020

ORR: Overall response rate; PFS: Progression free survival; OS: Overall survival.